Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

Summary Background We aimed to assess efficacy and tolerability of vorinostat in combination with bortezomib for treatment of patients with relapsed or refractory multiple myeloma. Methods In our randomised, double-blind, placebo-controlled, phase 3 trial, we enrolled adults (≥18 years) at 174 unive...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2013-10, Vol.14 (11), p.1129-1140
Hauptverfasser:	Dimopoulos, Meletios, MD, Siegel, David S, MD, Lonial, Sagar, MD, Qi, Junyuan, MD, Hajek, Roman, MD, Facon, Thierry, MD, Rosinol, Laura, MD, Williams, Catherine, MD, Blacklock, Hilary, MD, Goldschmidt, Hartmut, MD, Hungria, Vania, MD, Spencer, Andrew, MD, Palumbo, Antonio, MD, Graef, Thorsten, MD, Eid, Joseph E, MD, Houp, Jennifer, PharmD, Sun, Linda, PhD, Vuocolo, Scott, PhD, Anderson, Kenneth C, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Boronic Acids - administration & dosage Bortezomib Clinical trials Double-Blind Method Drug dosages Drug Resistance, Neoplasm - drug effects Female Follow-Up Studies Hematology Hematology, Oncology and Palliative Medicine Humans Hydroxamic Acids - administration & dosage Immunotherapy Lymphoma Male Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - mortality Multiple Myeloma - pathology Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Staging Patients Prognosis Pyrazines - administration & dosage Salvage Therapy Survival Rate Toxicity Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!